Research

Diabetes, cardiovascular drug targets

Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Pushing (anti-overdose) drugs

An automated alert to encourage clinicians to coprescribe naloxone for patients at risk of opioid overdose increased naloxone prescriptions per opioid prescription 16-fold.

Genetics and blood pressure

Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

A clue to an adverse drug event in children

Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Stomach

Molecular ‘switch’ may illuminate stomach disorders

An international team that included researchers from Vanderbilt University Medical Center has discovered a molecular switch that induces rapid proliferation of zymogen granule-secreting chief cells in the stomach to regenerate damaged tissue.

Andy Weiss, PhD, Caitlin Murdoch, PhD, and colleagues have characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins.

Study identifies first cellular “chaperone” for zinc, sheds light on worldwide public health problem of zinc deficiency

A team led by Vanderbilt researchers has described and characterized the first zinc metallochaperone: a protein that puts zinc into other “client” proteins.

1 19 20 21 22 23 54